Bavituximab and durvalumab combo to be evaluated in solid tumours
24 August 2015 | By Victoria White
AstraZeneca and Peregrine Pharmaceuticals are to evaluate the safety and efficacy of Peregrine’s bavituximab in combination with AstraZeneca’s durvalumab...